Premium
Ulipristal acetate shows promise for treatment of PMDD
Publication year - 2021
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30702
Subject(s) - irritability , ulipristal acetate , premenstrual dysphoric disorder , medicine , placebo , psychiatry , anxiety , alternative medicine , hormone , menstrual cycle , research methodology , population , environmental health , pathology , family planning
Women with premenstrual dysphoric disorder (PMDD) who received ulipristal acetate in a placebo‐controlled trial experienced improvement on a range of symptoms that included irritability and depression. Half of the participants receiving ulipristal acetate in the trial achieved full remission, the researchers reported.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom